| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
Form 4: Fennell George, Executive Vice President
Received 1,749 shares by exercise or conversion ($300K) |
| 05 Nov 2026 |
Form 4: Underberg Sharon E., EVP, GC & Corporate Secretary
Received 8,906 shares by exercise or conversion ($2.57M) · Sold 8,906 shares ($6.13M) |
| 05 Nov 2026 |
Form 4: Mazelsky Jonathan Jay, Director
Received 25,140 shares by exercise or conversion ($4.48M) · Sold 25,140 shares ($17.7M) |
| 05 Nov 2026 |
Form 4: Lane Michael, Executive Vice President
Sold 3,978.944 shares ($2.74M) |
| 05 Nov 2026 |
Form 4: Junius Daniel M, Director
Sold 1,200 shares ($845K) |
| 05 Nov 2026 | 144/A |
| 04 Nov 2026 | 144 |
| 04 Nov 2026 | 144 |
| 04 Nov 2026 | 144 |
| 04 Nov 2026 | 144 |
| 03 Nov 2026 |
Form 4: Hooley Joseph L, Director
Received 48 shares as a grant or award ($26.5K) |
| 02 Nov 2026 | 10-Q |
| 02 Nov 2026 |
8-K: Results of Operations and Financial Condition
Achieves third quarter revenue growth of 10% as reported and organic and CAG Diagnostics recurring revenue growth of 11% as reported and organic. |
| 30 Oct 2026 | SCHEDULE 13G |
| 09 Sep 2026 |
Form 4: Kingsley Lawrence D, Director
Received 2,203 shares by exercise or conversion ($252K) · Sold 2,203 shares ($1.17M) |
| 04 Sep 2026 | 144 |
| 24 Aug 2026 |
Form 4: Emerson Andrew, EVP, CFO and Treasurer
Received 265 shares by exercise or conversion ($47.2K) · Gave up 86 shares to cover exercise price or tax |
| 04 Aug 2026 | 10-Q |
| 04 Aug 2026 |
8-K: Results of Operations and Financial Condition
Achieves second quarter revenue growth of 10% as reported and 9% organic, and CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic. |
| 03 Aug 2026 |
Form 4: Hooley Joseph L, Director
Received 49 shares as a grant or award ($27.4K) |
Loading...